Insulin costs have been a controversial topic in pharma for years, with the leading manufacturers facing routine scrutiny for their pricing strategies. In a move poi...

Alkermes is drafting a former Major League Baseball player who has struggled with his own alcohol addiction as spokesperson for its alcohol dependency awareness...

Ohio has recently proved an alluring target for biopharmas of all sizes, from gene therapy player Sarepta Therapeutics to biotech-CDMO hybrid Forge Biologi...

“Project Dragonfly,” STA Pharmaceutical’s codenamed plan to build a massive manufacturing facility, has emerged from the cover of darkness, brought into the light by...

As Legend Biotech and Johnson & Johnson's multiple myeloma cell therapy prospect nears the FDA finish line, the companies are moving to carve out a manufact...

As Horizon Therapeutics' one-and-a-half-year-old thyroid eye disease med Tepezza starts to spread its wings, the drugmaker is standing up in-house manufacturing to h...

As Bristol Myers Squibb looks to guard Celgene’s top-selling cancer drug Revlimid from copycat competition, the company has inked a series of deals to welcome generi...

Amgen’s high-profile PCSK9 patent fight with Sanofi and Regeneron has attracted a who’s who of biopharma observers over the years, with many top compa...

In rapidly developing a COVID-19 vaccine—and a highly effective one at that—Novavax got the hard part right. But the logistics of manufacturing the vaccine ha...

For three years, Merck & Co.’s Keytruda has been the onlyimmuno-oncology drug allowed to treat cervical cancer. Now, thanks to a new clinical win, Merc...